0000874015-23-000242.txt : 20231228
0000874015-23-000242.hdr.sgml : 20231228
20231228191827
ACCESSION NUMBER: 0000874015-23-000242
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231226
FILED AS OF DATE: 20231228
DATE AS OF CHANGE: 20231228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'NEIL PATRICK R.
CENTRAL INDEX KEY: 0001564926
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 231523940
MAIL ADDRESS:
STREET 1: C/O IONIS PHARMACEUTICALS, INC.
STREET 2: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330336973
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2023-12-26
0
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001564926
O'NEIL PATRICK R.
2855 GAZELLE COURT
CARLSBAD
CA
92010
0
1
0
0
EVP CLO & General Counsel
1
Common Stock
2023-12-26
4
M
0
20825
47.34
A
61180
D
Common Stock
2023-12-26
4
S
0
20825
51.463
D
40355
D
Non-Qualified Stock Option (right to buy)
47.34
2023-12-26
4
M
0
20825
0.0
D
2021-01-03
2024-01-02
Common Stock
20825
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.30 to $51.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.
Patrick R. O'Neil
2023-12-28